Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : IACTA Pharmaceuticals
Deal Size : $100.0 million
Deal Type : Collaboration
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug
Details : Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharm...
Product Name : IC 800
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : IACTA Pharmaceuticals
Deal Size : $100.0 million
Deal Type : Collaboration